Linagliptin has a favourable safety and tolerability profile in patients with T2D.1

The risk of hypoglycaemia with linagliptin alone is low and the incidence was comparable to placebo. However, the most frequently reported adverse reaction was hypoglycaemia observed under the triple combination, linagliptin plus metformin plus sulphonylurea 14.6% versus 7.6% in placebo.1
Pancreatitis is an important but infrequent adverse drug reaction associated with linagliptin use.
The adverse drug reactions for linagliptin as described in the EU SmPC are provided in the table below.

* Based on post-marketing experience
** Based on lipase elevations >3xULN observed in clinical trials
Very common: ≥ 1/10, common: ≥ 1/100 to <1/10, uncommon: ≥ 1/1,000 to < 1/100, rare: ≥ 1/10,000 to < 1/1,000, very rare: <1/10,000 or not known: cannot be estimated from the available data
Use of DPP4 inhibitors has been associated with a risk of developing acute pancreatitis. In post-marketing experience of linagliptin there have been spontaneously reported adverse reactions of acute pancreatitis. Patients should be informed of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, Trajenta® should be discontinued; if acute pancreatitis is confirmed, Trajenta® should not be restarted. Caution should be exercised in patients with a history of pancreatitis.

Click here for information about special warnings and precautions for use.

Click here for comprehensive safety information in the Summary of Product Characteristics.